UCB's stock price seems, partly because of the recent share price rises, to be in line with most of the estimates. Most of the analysts say UCB is fairly priced now. Currently the company is being followed by 13 analysts. The average of the target prices for the stock equals 75,97 euros. This is around 0,2 percent more than the current price of 76,38 euros.
For this year UCB's revenue will be around 4,59 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 4,53 billion euros.
The analysts expect for 2018 a net profit of 863 million euros. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 4,59 euros. Based on this the price/earnings-ratio is 16,64.
Analysts expect a dividend of 1,2 euros per share. The dividend yield is then 1,57 percent. The average dividend yield of the pharmaceutical companies equals a moderate 0,5 percent.
UCB's market capitalization is based on the number of outstanding shares around 14,41 billion euros. The UCB stock was the past 12 months quite unstable. Since last January the stock is 11 percent higher. This year the stock price moved between 60 and 81 euro. Since 2008 the stock price is almost 212 percent higher.
At 14.38 the stock trades 0,08 percent lower at 76,38 euros.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.